Alembic Pharmaceuticals has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from February 28, 2024 to March 8, 2024. With this, for all its USFDA facilities, EIRs are in place.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.